Study suggests lithium could treat Alzheimer's

Lithium, used for decades to treat manic depression, has been shown in mice to block the production of proteins that form deposits in the brains of Alzheimer's patients, suggesting a potential role for the drug in treating the disease.

The researchers who conducted the experiments stressed that lithium has not been shown to work on Alzheimer's patients.

And lithium, though widely used to treat mental illness, has many side effects, including kidney damage. The problems are most pronounced in the elderly, who also face the greatest risk of Alzheimer's.

Alzheimer's is marked by the buildup in the brain of one protein, called amyloid beta, outside nerve cells and a second, called tau, that forms tangles in the cells. Alzheimer's affects about 12 million people worldwide.

Other possible approaches, including an experimental vaccine, have blocked the production of either amyloid beta or tau; lithium appears to tackle both, said the study's co-author, Dr. Peter Klein of the University of Pennsylvania.

Details of the mouse experiments appear in the journal Nature.

"Potentially, lithium could be used to reverse both the pathological features of Alzheimer's disease," Klein said.

Other scientists said the findings were encouraging, in part because lithium is a known drug.

"It seems you could block with a single medicine both of the major structural manifestations of the disease. This would be the first time that has been shown," said Dr. Sam Gandy, director of the Farber Institute for Neurosciences at Thomas Jefferson University in Philadelphia.

Zaven Khachaturian, senior science adviser to the Alzheimer's Association, said: "The chemistry of it is very exciting, very tantalizing."

By Andrew Bridges ~ The Associated Press

Lithium, used for decades to treat manic depression, has been shown in mice to block the production of proteins that form deposits in the brains of Alzheimer's patients, suggesting a potential role for the drug in treating the disease.

The researchers who conducted the experiments stressed that lithium has not been shown to work on Alzheimer's patients.

And lithium, though widely used to treat mental illness, has many side effects, including kidney damage. The problems are most pronounced in the elderly, who also face the greatest risk of Alzheimer's.

Alzheimer's is marked by the buildup in the brain of one protein, called amyloid beta, outside nerve cells and a second, called tau, that forms tangles in the cells. Alzheimer's affects about 12 million people worldwide.

Other possible approaches, including an experimental vaccine, have blocked the production of either amyloid beta or tau; lithium appears to tackle both, said the study's co-author, Dr. Peter Klein of the University of Pennsylvania.

Details of the mouse experiments appear in the journal Nature.

"Potentially, lithium could be used to reverse both the pathological features of Alzheimer's disease," Klein said.

Other scientists said the findings were encouraging, in part because lithium is a known drug.

"It seems you could block with a single medicine both of the major structural manifestations of the disease. This would be the first time that has been shown," said Dr. Sam Gandy, director of the Farber Institute for Neurosciences at Thomas Jefferson University in Philadelphia.

Zaven Khachaturian, senior science adviser to the Alzheimer's Association, said: "The chemistry of it is very exciting, very tantalizing."